ALB and hepatocellular carcinoma: 15.1 (7.8-29.3) for high vs. low urinary AFB1 metabolites; 10.4 (5.7-18.8) for high vs. low AFB1-albumin adducts; an additive effect of HBV and AFB1 exposure on HCC risk